BTG plc (BTG) Given Neutral Rating at J P Morgan Chase & Co
BTG has been the topic of several other research reports. Numis Securities Ltd restated a buy rating and issued a GBX 900 ($11.94) target price on shares of BTG plc in a report on Thursday, July 13th. Peel Hunt restated a hold rating and issued a GBX 680 ($9.02) target price on shares of BTG plc in a report on Wednesday, September 20th. Deutsche Bank AG restated a buy rating and issued a GBX 775 ($10.28) target price on shares of BTG plc in a report on Thursday, September 21st. Stifel Nicolaus restated a buy rating and issued a GBX 800 ($10.61) target price on shares of BTG plc in a report on Wednesday, August 30th. Finally, Shore Capital restated a not rated rating on shares of BTG plc in a report on Thursday, July 13th. Three investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. The company has a consensus rating of Buy and a consensus target price of GBX 780.33 ($10.35).
BTG plc (LON BTG) traded down 0.14% during mid-day trading on Friday, hitting GBX 713.00. 378,478 shares of the company were exchanged. The company’s market capitalization is GBX 2.75 billion. The company’s 50-day moving average is GBX 682.42 and its 200 day moving average is GBX 662.79. BTG plc has a 12-month low of GBX 528.36 and a 12-month high of GBX 738.50.
COPYRIGHT VIOLATION NOTICE: “BTG plc (BTG) Given Neutral Rating at J P Morgan Chase & Co” was published by Watch List News and is the property of of Watch List News. If you are reading this story on another site, it was stolen and republished in violation of United States and international copyright and trademark legislation. The legal version of this story can be viewed at https://www.watchlistnews.com/btg-plc-btg-given-neutral-rating-at-j-p-morgan-chase-co/1616074.html.
About BTG plc
BTG plc is engaged in the business of healthcare, focusing on Interventional Medicine therapies for liver cancer, emphysema and vascular disorders, specialty pharmaceuticals for acute care uses, and a licensing business. The Company operates through three segments: Interventional Medicine, Specialty Pharmaceuticals and Licensing.
Receive News & Ratings for BTG plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BTG plc and related companies with Analyst Ratings Network's FREE daily email newsletter.